Medivir
2.65
SEK
-3.28 %
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Less than 1K followers
-3.28%
-16.67%
-6.69%
-8.3%
-10.47%
-10.15%
-60.98%
-71.7%
-95.48%
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Read moreMarket cap
303.74M SEK
Turnover
1.64M SEK
Revenue
7.6M
EBIT %
-1,202.63 %
P/E
-
Dividend yield-%
-
Financial calendar
18.2
2025
Annual report '24
29.4
2025
Interim report Q1'25
7.5
2025
General meeting '25
ShowingAll content types
Anders Hallberg transfers his ownership to occupational pension insurance
Medivir to present at the Redeye Fight Cancer Event
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools